When was Proscia founded?

Proscia was founded in 2014 and raised its 1st funding round 2 years after it was founded.

Where is Proscia located?

Proscia is headquartered in Philadelphia, United States. It is registered at Philadelphia · City in Pennsylvania, United States.

How many employees does Proscia have?

As of Aug 31, 2026, the latest employee count at Proscia is 128.

Is Proscia a funded company?

Proscia is a funded company, having raised a total of $129M across 8 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jul 05, 2016.

How much is Proscia worth?

The latest valuation of Proscia is $***** as of Apr 21, 2025.

When was the latest funding round of Proscia?

Proscia's latest funding was a $***** Series C round on Mar 04, 2025, with participation from 9 investors. Its primary sector is Clinical Labs IT. In United States, the Clinical Labs IT sector has seen $446M in funding in 2026 to date.

Where does Proscia rank among its competitors?

Proscia ranks 45th amongst 1072 active competitors, of which 312 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Guardant Health, which secured $350M in Nov, 2025.

Who are the top competitors of Proscia?

Proscia's top competitors include Guardant Health, Natera and Lunit. Among them, Guardant Health secured the most recent funding round in November, 2025.

Proscia - 2026 Company Profile, Team, Funding & Competitors

Company Details

Proscia’s is a cloud-based software platform that clinic management, analysis, access, and collaboration for slide images in digital pathology. The features of the Proscia platform that allow users to improve whole slide image workflows include secure storage, annotation, and collaboration on digital biopsies. The company has developed a digital pathology platform called Concentriq that uses AI technology for computational pathology applications. The company has developed a tool that assists helathacre providers to diagnose cancer cells using image analysis technology.

Website: proscia.com
Social
Phone Number: +1 **********
Registered Address: Philadelphia · City in Pennsylvania, United States

Key Metrics

Founded Year

2014

Location

Philadelphia, United States

Stage

Series C

Total Funding

$129M in 8 rounds

Latest Funding Round

Series C, Mar 04, 2025, $*****

Post Money Valuation

$***** as on Apr 21, 2025

Investors

Triangle Peak Partners & 23 more

Ranked

45^th among 1072 active competitors

Employee Count

128 as on Aug 31, 2026

Similar Companies

Lunit & 236 more

View Proscia's full profile

Proscia is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Proscia Inc. CIN: 47-1450500 , United States, Active	Jun 30, 2014	-	85 (As on Dec 31, 2022)	-

Proscia has raised a total funding of $129M over 8 rounds. Its first funding round was on Jul 05, 2016. Its latest funding round was a Series C round on Mar 04, 2025 for $*****. 9 investors participated in its latest round. Proscia has 24 institutional investors.

Here is the list of recent funding rounds of Proscia:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 04, 2025	4867001	Series C	4948722	9493631	7656704	2580982
Dec 29, 2023	8903479	Series C	1697909	2750177	3977820	AIC & 2 more
Jun 03, 2022	5896480	Series C	2352076	8804879	7141596	Highline Capital & 7 more

Access funding benchmarks and valuations. Sign up today!

View details of Proscia's funding rounds and investors

The founders of Proscia are Coleman Stavish and David West.

Here are the details of Proscia's key team members:

Coleman Stavish: Co-Founder & CTO of Proscia and founder of 1 other company. They serve on the board of 1 company.
Contact Info: 1 email address
David West: Co-Founder & CEO of Proscia.
Contact Info: 1 email address

Proscia's Board of Directors

Proscia's board has 12 active members. Alex Niehenke, David West, Coleman Stavish, Jacob Doft, Tom Loftus, Robert Epstein, Stavish Coleman, Charles M. Hazard, David West, Jr., Neil L. Cohen, David West, Sr. and Alex Niehenke are independent board members.

Here is the list of Proscia's board of directors:

Name	Type	Representing	Status	Duration
Alex Niehenke	Independent board member	-	Current	5y 9m
mrogdge	Independent board member	-	Current	9y 4m
mpbbpwi	Independent board member	-	Current	9y 1m
wzyelur	Independent board member	-	Current	6y 7m
kkcjmwu	Independent board member	-	Current	4y 9m
mwkhavd	Independent board member	-	Current	5y 2m
kvelljf	Independent board member	-	Current	7y 1m
iuosgtx	Independent board member	-	Current	3y 7m
gkigila	Independent board member	-	Current	5y 5m
muwisrw	Independent board member	-	Current	3y 4m
xgefqyz	Independent board member	-	Current	3y 3m
pdcqkyt	Independent board member	-	Current	6y 6m

View details of Proscia's Founder profiles and Board Members

Proscia's employee count trend

Proscia has 128 employees as of Aug 26. Here is Proscia's employee count trend over the years:

Uncover Proscia's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Proscia include Guardant Health, Natera and Lunit. Here is the list of Top 10 competitors of Proscia, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	SoftBank Vision Fund, Lightspeed Venture Partners ... & 25 others	79/100
2nd	Natera 2004, Redwood City (United States), Public	Developer of cell-free DNA testing for oncology, women’s health, and organ health	$152M	Harmony Partners, Bain Capital Life Sciences ... & 18 others	77/100
3rd	Lunit 2013, Seoul (South Korea), Public	Developer of medical software for cancer screening and oncology diagnostics	$135M	InterVest, Shinhan Investment Corp & 25 others	71/100
4th	PathAI 2016, Boston (United States), Series C	Provider of digital pathology image management system for clinical labs	$255M	General Catalyst, General Atlantic & 22 others	70/100
5th	Foundation Medicine 2010, Cambridge (United States), Acquired	Provider of genomics-based diagnostics test for cancer	$96.5M	Redmile Group, Deerfield & 11 others	70/100
6th	Prenetics 2009, Hong Kong (China), Public	Online platform for genetic and diagnostic health testing that helps identify health risks	$67.6M	Apis Partners, Beyond Ventures & 22 others	69/100
7th	BillionToOne 2015, San Francisco (United States), Public	Provider of cell-free cancer liquid biopsy test	$389M	Hummingbird Ventures, Adams Street Partners ... & 31 others	69/100
8th	Ibex 2016, Tel Aviv (Israel), Series C	Provider of AI-powered diagnostic solutions for pathology	$114M	83NORTH, Kreos Capital & 6 others	68/100
9th	Myriad Genetics 1991, United States, Public	Developer of molecular diagnostics and personalized medicine for cancer	-	Grayhawk Capital, TriplePoint Capital & 6 others	68/100
10th	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	67/100
45th	Proscia 2014, Philadelphia (United States), Series C	Provider of an AI and cloud-based digital pathology solution for cancer diagnosis	$129M	Venture for America, Triangle Peak Partners ... & 22 others	59/100